



AGL 2022

51st GLOBAL CONGRESS ON MIGS

December 1–4, 2022 | Gaylord Rockies Resort and Convention Center | Aurora, Colorado

SYLLABUS

MAST-615: Master's Course in Exposure Retraction and Deep Dissection

SCIENTIFIC PROGRAM CHAIR
ANDREW I. SOKOL, MD

HONORARY CHAIR
CHARLES E. MILLER, MD

PRESIDENT
MAURICIO S. ABRÃO, MD, PHD

Table of Contents

Financial Disclosures	3
Course Program: Course Description, Learning Objectives, Course Outline	4
Laparoscopic Management of Ovarian Remnant T.T.M. Lee	5
Tackling Oncological and Other Complex Cancer Surgeries S.P. Puntambekar	9
Challenging Robotic Surgeries K.E. Patzkowsky	25
Transvaginal Complex Gynecologic Surgery J.B. Gebhart	32
Single-site vNOTES Routes for Challenging Surgeries X.Guan	38
Cultural and Linguistic Competency & Implicit Bias	39

Disclosure of Relevant Financial Relationships

As an ACCME accredited provider, AAGL must ensure balance, independence, and objectivity in all CME activities to promote improvements in health care and not proprietary interests of an ineligible company. AAGL controls all decisions related to identification of CME needs, determination of educational objectives, selection and presentation of content, selection of all persons in a position to control content, selection of educational methods, and evaluation of the activity. Course chairs, planning committee members, faculty, authors, moderators, and others in a position to control the content of this activity are required to disclose all financial relationships with ineligible companies. All relevant financial relationships are appropriately mitigated, and peer review is completed by reviewers who have nothing to disclose. Learners can assess the potential for commercial bias when disclosure, mitigation of conflicts of interest, and acknowledgment of commercial support are provided prior to the activity. Informed learners are the final safeguards in assuring that a CME activity is independent from commercial bias. We believe this mechanism contributes to the transparency and accountability of CME.

Asterisk (*) denotes no financial relationships to disclose.

PLANNER DISCLOSURE

The following members of AAGL have been involved in the educational planning and/or review of this course (listed in alphabetical order by last name).

Linda J. Bell, Admin Support, AAGL*

Linda D. Bradley, MD, Medical Director, AAGL*

Erin T. Carey, MD, MSCR

Honorarium: Med IQ

Research Funding: Eximis

Mark W. Dassel, MD*

Linda Michels, Executive Director, AAGL*

Vadim Morozov, MD

Speaker: AbbVie

Consultant: Medtronic, Lumenis

Erinn M. Myers, MD

Speakers Bureau: Intuitive Surgical

Amy J. Park, MD

Speaker: Allergan

Nancy Williams, COO, CME Consultants*

Harold Y. Wu, MD*

Xiaoming Guan, MD, PhD – Speakers Bureau: Applied Medical

Kristin E. Patzkowsky, MD*

SCIENTIFIC PROGRAM COMMITTEE

Andrew I. Sokol, MD - Medical Legal Defense: Johnson & Johnson

Angela Chaudhari, MD - Consultant: Johnson & Johnson

Cara R. King, DO*

Mario Malzoni, MD – Consultant: KARL STORZ

Jessica Opoku-Anane, MD, MS – Consultant: Boston Scientific; Myovant Sciences; AbbVie

Shailesh P. Puntambekar, MD, PHD*

Frank F. Tu, MD, MPH*

Jonathon M. Solnik, MD – Consultant: Olympus;

Medtronic; Stockholder: Field Trip Health, Inc.; Felix Health

Linda D. Bradley, MD, Medical Director*

Linda Michels, Executive Director, AAGL*

FACULTY DISCLOSURE

The following have agreed to provide verbal disclosure of their relationships prior to their presentations. They have also agreed to support their presentations and clinical recommendations with the “best available evidence” from medical literature (in alphabetical order by last name). John B. Gebhart, MD, MS – Advisory Board – UroCure;

Royalty: Elsevier, UpToDate

Xiaoming Guan, MD, PhD – Speakers Bureau: Applied Medical

Ted T.M. Lee, MD*

Kristin E. Patzkowsky, MD*

Shailesh P. Puntambekar, MD, PhD*

MAST-615: Master's Course in Exposure Retraction and Deep Dissection

Chair: Xiaoming Guan, MD, PhD, Kristin E. Patzkowsky, MD

Faculty: John B. Gebhart, MD, MS, Ted T.M. Lee, MD, Shailesh P. Puntambekar, MD, PhD

Course Description

Pursuing the perfect surgical skills with optimum surgical routes and platforms for handling challenging surgeries is a fantasy of MIGS surgeons. As we all have known, no see (exposure) with no cut and sailing in uncharted waters (anatomy) with no jumps (deep dissection) are common difficulties faced by surgeons. Exposure retraction and deep dissection are the cornerstone of tackling the situations for the surgeons in the OR, nonetheless with preparation even the worst scenarios ahead can be conquered easing the surgeons' stress. Expert physicians will provide an in-depth discussion on exposure retraction and deep dissection techniques through multitudes of numerous complex cases, including laparoscopic and robotic platform, as well as multiple, single site and transvaginal routes.

The course will also cover novel transvaginal NOTES surgeries for complex cases such as deep infiltrated endometriosis and sacrocolpopexy as alternative route for most minimally invasive route. This course will illustrate the anatomical dissection of uterine transplant, which will bring you multiple views of surgical concepts of exposure and deep dissection through one of most complex surgical types. This course will have a practical focus on teaching tips and tricks for you to apply to your operating room and incorporate them into your pre-operative assessment to ensure your success in handling even the most complex cases.

Learning Objectives

At the conclusion of this course, the participant will be able to: 1) Apply exposure retraction and deep dissection surgical skills on various complex cases in your own practice; 2) Implement a multiplatform technique for even the most complex surgeries; surgeon can absorb the tips and tricks for his most familiar surgical platform; 3) Illustrate the pros and cons of the different routes in challenging surgeries; and 4) Compare how differently specialized surgeons utilize different techniques for the advanced cases.

Course Outline

2:30 pm	Welcome, Introduction and Course Overview	X. Guan/K.E. Patzkowsky
2:35 pm	Laparoscopic Management of Ovarian Remnant	T.T.M. Lee
3:00 pm	Tackling Oncological and Other Complex Cancer Surgeries	S.P. Puntambekar
3:25 pm	Challenging Robotic Surgeries	K.E. Patzkowsky
3:50 pm	Transvaginal Complex Gynecologic Surgery	J.B. Gehart
4:15 pm	Single-site and vNOTES Routes for Challenging Surgeries	X. Guan
4:40 pm	Questions & Answers	All Faculty
5:00 pm	Adjourn	

Ovarian Remnant: Diagnosis, Prevention and Management

Ted Lee, M.D.
Director, Minimally Invasive Gynecologic Surgery
Magee Womens Hospital

1

Conflict of Interest Disclosure

None

Objectives

- Describe risk factor and presenting symptoms of ovarian remnant.
- Explain the key diagnostic modalities for ovarian remnant.
- Recognize the surgical risks associated with surgical management of ovarian remnant.
- Use anatomic approach in the prevention and management of ovarian remnant

3

Ovarian Remnant : Definition

- Retention of ovarian tissue with prior documentation of prior salpingoophrectomy.

4

Common Risk Factors

- Endometriosis
- Previous surgeries
- PID

5

Ovarian Remnant: Initial Clinical Presentations

Studies	Mayo 2005	Mayo 2007	Magee 2011
Pain	48% (89/186)	90 % (18/20)	96 % (29/30)
Mass	57% (105/186)	10 % (2/20)	4% (1/30)

Kho RM, Magrino JE, Magtibay PM. Pathologic findings and outcomes of a minimally invasive approach to ovarian remnant syndrome. FertilSteril. 2007;87

Magtibay PM, Nyholm JL, Hernandez JL, Podraz KC. Ovarian remnant syndrome. Am J Obstet Gynecol. 2006;193

Arden D, Lee TM. Laparoscopic Excision of Ovarian Remnants: A Retrospective Cohort Study with Long-Term Follow-Up. J Min Inv Gyn 2011; 18 (2)

6

Ovarian Remnant: Symptoms

Studies	Mayo 2005	Magee 2011
Pelvic Pain	66%	96% (29/30)
LLQ pain		55.2% (16/29)
RLO pain		27.6% (8/29)
Lower abdominal pain		17.2% (5/29)
Dyspareunia	26%	56.7% (17/29)
Dyschezia	6%	36.7% (11/29)
Dysuria	7%	20% (6/29)

Magtibay PM, Nyholm JL, Hernandez JL, Podraz KC. Ovarian remnant syndrome. Am J Obstet Gynecol. 2005;193.

Arden D, Lee TM. Laparoscopic Excision of Ovarian Remnants: A Retrospective Cohort Study with Long-Term Follow-Up. J Min Inv Gyne. 2011; 18 (2).

7

Ovarian Remnant: Patient Characteristics

Studies	Mayo 2005	Nezhat 2005	Mayo 2007	Magee 2011
Age (years)	37.6	38.7	48	38.6
Previous Laparotomy	1.4	2	2.7	2.5
Previous Laparoscopy	0.77	2	1.4	1.9
Previous Surgical Attempts	35%	15.6%	0%	17%

Kho RM, Magrina JF, Magtibay PM. Pathologic findings and outcomes of a minimally invasive approach to ovarian remnant syndrome. FertilSteril. 2007;87.

Magtibay PM, Nyholm JL, Hernandez JL, Podraz KC. Ovarian remnant syndrome. Am J Obstet Gynecol. 2005;193.

Arden D, Lee TM. Laparoscopic Excision of Ovarian Remnants: A Retrospective Cohort Study with Long-Term Follow-Up. J Min Inv Gyne. 2011; 18 (2).

Nezhat C, Kearney S, Malik S, Nezhat C, Nezhat F. Laparoscopic management of ovarian remnant. Fertil Steril. 2005;83.

8

Ovarian Remnant after Unilateral Salpingoophorectomy

Studies	Nezhat 2005	Magee 2011
	30% (19/64)	20% (6/30)

Arden D, Lee TM. Laparoscopic Excision of Ovarian Remnants: A Retrospective Cohort Study with Long-Term Follow-Up. J Min Inv Gyne. 2011; 18 (2).

Nezhat C, Kearney S, Malik S, Nezhat C, Nezhat F. Laparoscopic management of ovarian remnant. Fertil Steril. 2005;83.

9

Ovarian Remnant: Diagnosis

Studies	Mayo 2005	Nezhat 2005	Magee 2011
Ultrasound	93%	80.4% (US & CT)	89.6%
Premenopausal FSH (<30 IU/dL)	69%	NA	59.1%
Premenopausal E2 (>35 pg/mL)	63%	NA	70.6%

Magtibay PM, Nyholm JL, Hernandez JL, Podraz KC. Ovarian remnant syndrome. Am J Obstet Gynecol. 2005;193.

Arden D, Lee TM. Laparoscopic Excision of Ovarian Remnants: A Retrospective Cohort Study with Long-Term Follow-Up. J Min Inv Gyne. 2011; 18 (2).

Nezhat C, Kearney S, Malik S, Nezhat C, Nezhat F. Laparoscopic management of ovarian remnant. Fertil Steril. 2005;83.

10

Location of Ovarian Remnant

Location	Magee 2011
Left	60% (18/30)
Right	23.3% (7/30)
Bilateral	16.7% (5/30)

Arden D, Lee TM. Laparoscopic Excision of Ovarian Remnants: A Retrospective Cohort Study with Long-Term Follow-Up. J Min Inv Gyne. 2011; 18 (2).

11

Location of Ovarian Remnant



12

Complexities of Ovarian Remnant Surgeries

Studies	Nezhat 2005	Magee 2011
Enterolysis	90.6 % (58/64)	90.0% (27/30)
Uretolysis	73.4% (47/64)	93.3 % (28/30)

Arden D. Lee TM. Laparoscopic Excision of Ovarian Remnants: A Retrospective Cohort Study with Long-Term Follow-Up. J Min Inv Gynec 2011, 18 (2).

Nezhat C, Kearney S, Malik S, Nezhat C, Nezhat F. Laparoscopic management of ovarian remnant. Fertil Steril. 2005;83

13

Intraop Complications/Complexities of ORS Surgeries

Studies	Mayo 2005	Nezhat 2005	Magee 2011
Bowel injury with primary repair	5%		13.3% (4/30)
Bowel injury with primary resection		7.8% (5/64)	10% (3/30)
Bladder Injury with primary repair	2%	1.6%(1/64)	6.7%(2/30)
Ureteral injury/repair	1%	1.6 (1/64)	0
Transfusion	12%	0	0
Conversion	NA	3.1% (2/64)	0
Recurrences/ Persistence	1%	12.5% (8/64)	0


14

Post-op Complications of ORS Surgeries


Studies	Mayo 2005	Nezhat 2005	Magee 2011
Vesicovaginal Fistula	0	1.6% (1/64)	0
Ureteral Obstruction	2%	0	0
DVT or PE	2%	0	0
Ileus or partial SBO	8%	0	0
Transfusion	12%	0	0
Conversion	NA	3.1% (2/64)	0
Recurrences/ Persistence	1%	12.5% (8/64)	0
Reoperation for Pain or Remnant	9%	7.8 % (5/64)	6.6% (2/30)

15

Preventing Ovarian Remnant




Preventing Ovarian Remnant




17

Ovarian Remnant Prevention




18

Ovarian Remnant Prevention




19

Laparoscopic Resection of Ovarian Remnant 1




20

Laparoscopic Resection of Ovarian Remnant 2- Hidden Pararectal



21

Laparoscopic Resection of Ovarian Remnant 3 Hydronephrosis



22

References

- Magtibay PM, Nyholm JL, Hernandez JL, Podraz KC. Ovarian remnant syndrome. Am J Obstet Gynecol. 2005;193(6):2062-6.
- Arden D, Lee T. Laparoscopic excision of ovarian remnants: retrospective cohort study with long-term follow-up. J Minim Invasive Gynecol. 2011;18:194-199.
- Nezhat C, Kearney S, Malik S, Nezhat C, Nezhat F. Laparoscopic management of ovarian remnant. Fertil Steril. 2005;83:973-978.
- Kho RM, Magrina JF, Magtibay PM. Pathologic findings and outcomes of a minimally invasive approach to ovarian remnant syndrome. Fertil Steril. 2007;87(5):1005-9.

23

Conclusion

- High index suspicion is essential for the diagnosis of ovarian remnant in patients with high risk factors.
- Imaging and/or premenopausal hormones will detect close to 100% of ovarian remnant.
- Ovarian remnant is a surgically challenging condition even in the best of hands.
- Risk of visceral injury and its associated repair is high. Discussion of the specific risks should be carefully documented in the informed consent process.
- Adherence to the anatomic approach to salpingoophorectomy will minimize the risk of ovarian remnant.
- Laparoscopic resection of ovarian remnant is safe and feasible in the majority of cases.


24

APPLIED ANATOMY LESSONS FROM UTERINE TRANSPLANT SURGERY




Dr Shailesh Puntambekar
Medical Director,
Galaxy Care Multispeciality Hospital, Pune

Hello Everyone



Life is a process of evolution and
anyone who thinks the current world
order is OK does not get what
evolution is all about.

— Leroy Hood —



HISTORY

IN 2000 1ST UTERINE TRANSPLANT DONE IN SAUDI
AFTER 99DAYS UTERUS REMOVED DUE TO NECROSIS

1st successful uterine transplants from cadaver in turkey in
2009

In 2020 she got pregnant after 29 cycles ivf after 9 years
she delivered baby boy at 28wks by lscs

2ND was done in 2011

Our 4th country to do uterine transplant
Our was the 12th baby born after uterine
transplant in the world


WHAT IS DIFFERENT IN UTERINE TRANSPLANT????

- Non vital organ transplant
- Only organ outside the abdomen and thorax
- creates life (vs others give life)
- Wait for 17 months to get the ultimate result
- No life long deformities or ailments in future after removal of uterus
- No need of life long immunosuppression
- First Hand Experience of Gestational Motherhood...the joy is speechless



UTERINE TRANSPLANT

Uterine transplant opened doors when all others remained shut



FIGO COMMITTEE FOR ETHICAL ASPECTS OF HUMAN REPRODUCTION & WOMAN HEALTH

Deemed Uterine Transplant Unethical given the lack of data on safety & efficacy

CRITERIA for ethical feasibility of Uterine Transplant " is an attempt to b


MONTREAL CRITERIA FOR SELECTION

- SELECTION CRITERIA FOR DONOR
- SELECTION CRITERIA FOR RECIPIENT
- SELECTION OF YOUR "TRANSPLANT TEAM"

PREPARATION



INSPIRED FROM



INSPIRED FROM

LAPAROSCOPIC RADICAL TRACHELECTOMY

WE ASKED

- Why ONLY uterine vessels, why Ovarian vessels not considered ??
- Why 14 hrs were spent for such a surgery ??
- Why put a patient through 14 hrs of Anaesthesia ??
- What About the PROLONGED ISCHEMIA TIME ?
- Why Can't it be done by Laparoscopy ??

Can It be done in India ??



A Right Approach Towards Uterine Transplant Can Be Achieved Through CADAVERIC DISSECTION



Dr. Shailesh Puntambekar demonstrating
pelvic dissection

A big Thank You to Marcello and team!



OUR TEAM

Chief Operating Surgeon
Vascular Surgeon
Plastic Surgeon
Gynaecologists
High Risk Obstetricians
Transplant Physicians

IVF Specialists
Neonatologist
Assisting Surgeons
Transplant Psychiatrist
Transplant Counsellor
Transplant Co-ordinator




STEPS

Infundibulopelvic (IP) ligament was
skeletonized upto the brim. Ovarian
artery
and vein were dissected till their entry
into the IP ligament.

STEP

pararectal and paravesical spaces
were dissected upto the Levator
Ani muscle


Pararectal Space




Ureter Divides Pararectal Space into

Medial - Okabayashi

Lateral - Latzko





PARARECTAL SPACE

Medial Approach

Lateral approach

Entering the Space following separation of Posterior fascia of Transverse Cervical Ligament and Int. Iliac vessel Sheath from the main body

Medial Pararectal Space

Lateral Pararectal Space



Contains
Superior Hypogastric
Plexus and Hypogastric
nerves

Contains the
pelvic splanchnic nerves
and uterine artery

Essential in Nerve-Sparing
Radical Hysterectomy


Best place to clamp Uterine Artery

Essential in Any
Hysterectomy

Paravesical Space



Content:
Obturator Neurovascular bundle
Lymphatics
BEWARE OF CORONA MORTIS



Uses
Best Access to Lateral pelvic Wall for
Optimal Oncological Clearance & Lymph
Node dissection

Paravesical Space

STEP 3

The pouch of Douglas was dissected. Rectovaginal space was dissected upto the Levator Ani

KNOWLEDGE OF PELVIC AVASCULAR SPACES IS MUST



STEP

The key step in this surgery is the **ureteric dissection**

The Uterine artery and vein have **arborisation** and small branches around the ureter were carefully separated, ligated or clipped. Thus, **the left ureter was lateralized**, totally separated from all around and completely denuded

TRACING OF URETER

If there is venous bleeding then the ureter is lifted anteriorly and bleeding to be controlled and if its arterial bleeding it come from the top

URETERIC TUNNEL DISSECTION

UNDERSTANDING OF ANTERIOR PARAMETRIUM HELPS

KEY STEPS


- DISSECTION OF ANTERIOR & POSTERIOR CERVICO-VESICAL LIGAMENT.
- OPENING OF YABUKI SPACE
- TRACING URETER UPTO THE URETERO-VESICAL JUNCTION
- IDENTIFYING INFERIOR VESICAL VEIN



Ureters Are Prone To Fistulas Due To Complete Devascularisation Which Can Be Prevented By

Prophylactic
DJ
Stenting


Omental Wrapping
around Ureters



Innovations in Anatomy

- The Internal Iliac artery distal to the origin of the Uterine artery was ligated.
- The lateral branches were ligated and clipped.
- The Internal Iliac vein was dissected from the origin till the insertion of the Uterine veins.
- The lateral Ilioligular branch and Obturator veins were ligated.
- Vaginal veins and the Pudendal veins were ligated. The entire vein distal to the insertion of the Uterine vein was ligated. Thus, we get a good length of Uterine Vein

Anterior branch of Internal Iliac artery along with the Uterine artery was skeletonized till its origin, on the left side



6 cms of branch-free Ant Division of Int. Iliac Art - essential for ligation

Internal Iliac Vessels




Bifurcation of Int. Iliac artery is 2-3 cms below bifurcation of Common Iliac Artery

First branch arises at 6 cms - Uterine Artery

The next branch after Uterine artery - Superior Vesical Artery

Branches of Anterior Division of Internal Iliac Artery




Innovations in Anatomy

Internal Iliac veins are very deeply seated difficult to harvest, very time consuming and too much morbidity to the donor

The Finer Details Of Uterine Artery Was Examined And Dissected


UTERINE ARTERY BRANCHES CLIPPING

ABANDON ONE SIDE OVARIAN VEIN AND ARTERY



The uterus can survive with **ONE UTERINE ARTERY** and **ONE OVARIAN VEIN**

Advantages of Abandoning Uterine Vein



No traction of lower uterus while formation of supports


Easy Suturing of Mackenrodt's ligament

Least morbid procedure


Innovations In Vascular Anastomosis

Left Side


Right Side




THE INDIAN APPROACH TOWARDS UTERINE TRANSPLANT



Numerous Trial Bench Surgeries in routine Hysterectomy Specimens Enabled Us To Unlock The Secrets



The secret lies in Ovarian veins



Innovations in anatomy

CERVICOVESICAL FASCIA

CERVICO - VESICAL FASCIA

Covers the cervix Anteriorly and Laterally
Continues as the Endopelvic Fascia as it reaches the Levator Ani

Bladder dissection will lie
Anterior to the fascia

The venous plexus lies
Beneath the fascia

The Uterine Vessels lie Above the fascia, thus exposing them

The Vagina is accessible after dissection of the fascia for colpotomy

If these steps are followed sequentially,
would achieve bloodless dissection

BLADDER DISSECTION PRESERVING THE CERVICOVESICAL FASCIA (PUSH THE BLADDER AWAY)

the bladder, dissection to be done remaining above the cervicovesical fascia to stay away from the

Dissection of Cervicovaginal fascia

IMPLICATIONS OF VEINS LYING UNDERNEATH THE FASCIA

- APPLIED - STAY ABOVE FASCIA
- IF WANTS TO CONTROL BLEEDING - HOLD & COAGULATE FASCIA BLEEDING WILL STOP

COLPOTOMY

- Colpotomy was done by separating the vagina anteriorly, from the posterior surface of bladder so as to get approximately 1.5 cms of vagina, and posteriorly, from rectum.

Transplant Surgery


Laparoscopic Dissection OF DONOR uterus

Laparoscopy Assisted Uterine transplant

Pedicle lengths achieved with Open surgery (Sweden)



Pedicle lengths achieved with Laparoscopic surgery



Perks of Laparoscopy

ADVANTAGES of Laparoscopy

SWEDEN 2012

Modality : Open
Total Duration : 14 hrs

DURATION
DONOR : 10 HR 7 MIN
RECIPIENT : 4 HR 55 MIN

BLOOD LOSS DONOR : 0.7 LT
RECIPIENT : 0.6 LT

Outcome: Successful

FIRST MENSES: 43 DAYS

INDIA 2018

Modality: Laparoscopic
Total Duration : 8-10 hrs

DURATION
DONOR : 4 HOURS
RECIPIENT : 4 HOURS
TOTAL ISCHEMIC TIME : 45 MIN

BLOOD LOSS DONOR : 0.5 LT
RECIPIENT : 0.5 LT

Outcome: Successful

FIRST MENSES: 48 DAYS

BENCH PREPARATION

Uterus was placed on ice slush flooded with cold Custodial solution. Bilaterally, Internal Iliac artery and veins and Ovarian vessels were identified, dissected, skeletonized, terminal openings prepared and kept ready for anastomosis

BENCH SURGERY

GRAFT PREPARATION

Demonstrating utero ovarian anastomosis

VASCULAR BED PREPARATION

OUR CONTRIBUTION TO WORLD CONTINUES..

Novel Anastomotic Technique for Uterine Transplant Using Utero-ovarian Veins for Venous Drainage and Internal Iliac Arteries for Perfusion in Two Laparoscopically Harvested Uteri

Shalish Puntambekar¹, Seema Puntambekar², Milind Telang³, Pankaj Kukarni⁴, Sharda Dole⁵, Mangesh Pansar⁶, Ravindra Sathe⁷, Nikhil Agarhedekar⁸, Neeta Wary⁹, Sandesh Kade¹⁰, Manoj Manchekar¹¹, Mihir Chitale¹², Hirav Parekh¹³, Kaji Parekh¹⁴, Mahul Mehta¹⁵, Bhushan Khotkar¹⁶, Joy Shankar Jana¹⁷, Anusha Pare¹⁸, Shalendra Kanade¹⁹, Ashay Sathe²⁰, Shreshth Harkar²¹, Ashish Jadhav²², Tejashree Sakre²³, Meenakshi Chate²⁴, Raviraj Tiruke²⁵

Shalish Puntambekar MS, Seema Puntambekar MS, Milind Telang MD, Pankaj Kukarni MD, Sharda Dole MCH, Mangesh Pansar MS, Ravindra Sathe MS, Nikhil Agarhedekar MCH, Neeta Wary MS, Sandesh Kade MS, Manoj Manchekar MS, Mihir Chitale FCPS, Hirav Parekh MS, Kaji Parekh MS, Mahul Mehta MS, Bhushan Khotkar MD, Joy Shankar Jana MD, Avinash Pare MD, Shalendra Kanade MD, Ashay Sathe DM, Shreshth Harkar MD, Ashish Jadhav MS, Tejashree Sakre MS, Meenakshi Chate MS, Raviraj Tiruke MS

PII: S1553-4650(18)31431-6
DOI: <https://doi.org/10.1016/j.jmig.2018.11.021>
Reference: JMG 3718



INDIA IS THE FIRST COUNTRY TO HAVE PERFORMED UTERUS TRANSPLANT IN HUMANS IN ASIA!

J. Clin. Med. 2018, 7, 201

8 of 12

Table 3. Preclinical studies and human UTX research in Asia.

Country	Team Leader	Performance of UTX	Pre-Clinical Study in Human UTX	Main Outcome	Approval of Ethical Committee
Wai L.	Yes	Non-human whole cadaver UTX		Successful uterine preservation and recovery of uterine function	Done
Wang YJ/ Chen GW	Yes		Cold ischemic preservation of uterine tissue, vessel anastomosis (8 cases), uterine perfusion and ischemic study of cases * All uteri performed free brain dead donors	Show that uterine tissues are nearly normal in 23 h after perfusion Confirm different perfusion methods via external iliac artery or abdominal aorta	Done
China	Hua QJ/Liu Y	No	UTX with living donor by laparoscopic donor surgery	Removal of transplanted uterus 30 days after surgery (acute left uterine vein thrombosis)	Ongoing
Huo XP	No	No			No
Chen ZJ	No	Allowable cold ischemic time in human uterus with IFA (Dendrocytophyllum longicaule) as perfusion (donor)		Human uterine myometrial tissue thickness and ischemia for at least 1 h in UTX isolation	Done
Yao YQ	No	No			No
Zhang WY	No	No			No
India	Puntambekar S	Yes	UTX with living donor by laparoscopic donor surgery	First successful delivery in Asia	Done
Japan	Endo I	No	Cadaveric uterine dissection (1 case) * 2 cases performed with Singaporean team	Successful dissection of vessels surrounding the uterus and retrieval of the uterus	No
Yamamoto O	No	No			No
Korea	Song MJ	No	No		No
Singapore	Tan HK	No	Cadaveric uterine dissection (3 cases) * 2 cases performed with Japanese team	Successful dissection of vessels surrounding the uterus and retrieval of the uterus	Done
Sri Lanka	Liu WC	No	No		No

S. Zaidi, A. Di Luca, E. Mannelli

Table 1. UTX historical timeline


Laparoscopic date of surgery	Type of UTX	Organ origin	Outcome
Dresden Maternal Women's Clinic, Germany 2001	The first uterus transplant in history	Unknown	Death, on September 13, 1931, three months after the surgery, of cardiac arrest. Specimens for the infection and the development of the infection were rejected by the transplanted uterus and the development of the infection was not observed.
Saudi Arabia April 2009	A 26-year-old with a history of hysterectomy due to post-partum hemorrhage	First ever from live donor, a 46-year-old	Uterine artery and vein had to be removed after 99 days due to blood clots and postoperative infection.
Akdeniz University Hospital in Antalya, Turkey 2011	A 21-year-old patient with Beckwith-Wiedemann	First ever UTX from deceased donor	The transplanted uterus was viable. The patient underwent cesarean transfer 14 months after the operation, presented two pregnancies, spontaneous abortion before 14 weeks of gestation.
Sakagami University Hospital in Fukushima University, Sweden 2012	The first clinical trial involving two women, receiving first from live donor, second from deceased donor. Both patients, aged 32 and 37 years, both lacked a uterus, one woman had been removed due to endometrial cancer and the other was born without one.	First ever uterine transfer to live donor transplants	One of the patients successfully carried a pregnancy to term, giving birth to a baby boy to a woman in September 2014 (first birth from live donor UTX)
Cleveland Clinic, Laping Sheng 2nd February 2016	36-year-old woman	From deceased donor, a 40-year-old, shown to be healthy according to Chinese	The transplant failed due to a condition after a viral infection by the local artery compromising the blood supply of the uterus and the pregnancy, removed on 16th March 2016
Hospital de Clinica in São Paulo, Brazil September 2016	The recipient is a 32-year-old who had Major-Rokitansky-Kuster-Hauser syndrome	From deceased donor, a mother of three in her mid-40s who died from bleeding on the brain	First ever successful pregnancy, a healthy baby girl was born in December 2015 (first birth from deceased donor UTX)
Bay for University Medical Center, Dallas, United States December 2017	Woman who had been born without a uterus	Uterus donated from a 26-year-old non-directed living donor	The first birth as a result of a womb transplant in the United States
St. Mary's Hospital in Pune, Maharashtra India 15th May 2017	36-year-old patient born without a uterus due to a congenital	First ever donor-recipient between two women	Successful delivery through a Cesarean section at Gairly Care Hospital on October 2018
Centro Maternal, Valencia 2nd June 2018	patient suffered from uterine artery	but was uterus from her 46-year-old mother who was the first UTX performed in the United States and North Africa	

OUR SUCCESS WAS CELEBRATED BEFORE THE WORLD AT GLOBAL CONGRESS OF AMERICAN ASSOCIATION OF GYNAECOLOGICAL LAPAROSCOPISTS IN 2018




WHEN OUR WORK WAS ACKNOWLEDGED...


RECENT PUBLICATIONS WE CONTRIBUTED TO SCIENCE!



OUR CONTRIBUTION TO WORLD CONTINUES...



WE HAVE BEEN CITED BY...




A LETTER OF APPRECIATION MEANT A LOT

"If no one can repeat it. Its not worth Anything. We owe to the patients to be open."
 -Dr. Liza Johannesson
 Co surgeon to the world first uterine transplant giving a statement to TIME MAGAZINE

WE DID NOT ONLY THE FIRST LAPAROSCOPIC RETRIEVAL OF DONOR UTERUS

BUT ALSO THE FIRST CENTRE FOR LAPAROSCOPIC VASCULAR ANASTOMOSIS



Covid

- 1.no transplants could be done
- 2.patients were not able to take immunosuppressants
- 3.second patient is pregnant
- 4.world wide transplant programmes have taken back seat


current status

- 1.Cadaveric transplants done in two patients
- 2.Robotic donor uterine transplants done
- 3.Spain and Brazil did the transplant using our technique of ovarian veins
- 4.more than 90 transplants done
- 5.forty three babies delivered

POST OPERATIVE MONITORING




- Routine Blood Investigations
- Specific Investigations-



- Non- Invasive**
 - USG TO MEASURE ET. ECHOGENESITY
 - Colour Doppler - TO MEASURE VELOCITY IN ANASTOMOTIC VESSELS
- Invasive**
 - Colposcopic Examination,
 - Biopsy TO DETECT EARLIEST MANIFESTATION OF REJIN CONFIRMED MANNER ECTION

Hysteroscopy : the best tool for detection of early graft rejection

DOPPLER FLOW



Doppler Images And Videos

DOPPLER S/O DECREASED FLOW


POST UTX PT WITH
DECREASED FLOW AFTER
1 YEAR
GIVEN
INJ HEPARINE PRIOR TO
IVF



Challenges During Ivf

1. Unpredictable ovarian response .
2. Which protocol to be used?
3. Challenges in titrating gonadotropin dose rationale.
4. Difficult ovum pickup-
Ovaries are lateral to external iliac vessels in women with uterine agenesis.
Bowel/bladder injury.
5. Different anatomy (pelvic kidneys-MRKH2).
6. Poor quality embryos.
7. Increase chance of cycle cancellation.
8. Change in axis and cervical stenosis,small vagina-
Difficult et
- 9.Improper vaginoplasty,higher placement of uterus, fibrosis between vagina and external os- difficult et.
- 10.All procedures under GA
11. Abdominal et (may required).

Difficulty In Embryo Transfer



Embryo transfer

DIFFICULTIES IN IMPLANTATION

- ENDOMETRIUM PRIMING AFTER CERTAIN AGE NOT GOOD
- HIGHER RESISTANCE IN UTERINE ARTERIES IN DONOR UTERUS
- RECEPTIVITY OF ENDOMETRIUM NOT GOOD
- DISTENSIBILITY OF UTERUS IS AT RISK
 - IMMUNOLOGICAL FACTORS

ONLY 30% IS FERTILITY RATE AT ANY GOOD IVF CENTERS

DIFFICULTIES IN TEAM UP

- IN INDIA - SINCE LAST 3 YEARS NO STATE HAS GIVEN COMMITTEE APPROVAL ONE OF FACTOR BEING COVID PANDEMIC
- UTX TEAM WORK TASK - ALL DOCTORS (SURGEONS, OBGYN, VASCULAR SURGEON, ANAESTHETIST ETC.) TO COME TOGETHER IS DIFFICULT

Removal



Removal of Uterus
(Hysterectomy) to be done :

✦ After completion of
Family

✦ Signs of Graft Rejection

✦ Signs of Infection/Septicaemia

Complication Post Transplant

Post Transplant Hysterectomy

Atrophic uterus post Uterine Transplant

LESSONS WE LEARNT...

- ♦UTX IS COMPLETE ANSWER TO ABSOLUTE UTERINE FACTOR INFERTILITY
- ♦UTERO-OVARIAN ANASTOMOSIS
- ♦SINGLE SIDE VASCULAR ANASTOMOSIS IS SUFFICIENT
- ♦OMENTAL WRAPPING OF UTER OR PROPHYLACTIC DJ-STENTING TO PREVENT URETERIC FISTULAS
- ♦LAPAROSCOPIC ASSISTED DONOR RETRIEVAL OF UTERUS- long pedicle lengths AND Wider anastomosis
- ♦BETTER VASCULARITY TO THE ORGAN ,BETTER ADAPTATION DURING PREGNANCY TO ACCOMMODATE EXTRA BLOOD FLOW.

LESSONS WE LEARNT...

- ♦IMMUNOSUPPRESSANT SHOULD GIVE ONE DAY PRIOR TO SURGERY AND SHOULD CONTINUE FROM POST OP DAY ONE.
- ♦RIGOROUS POSTOP MONITORING -to detect early signs of rejection
- ♦EMBRYO TRANSFER SHOULD NOT DELAY MORE THAN 6 MONTHS
- ♦MORBIDITY AND MORTALITY IS VERY LESS


AGAIN MADE HISTORY

- 1ST POST COVID UTERINE TRANSPLANTS
- 2 TRANSPLANTS IN ONE DAY IN RECORD BREAKING TIME (<12 HOURS)
- THAT TOO IN OTHER CENTER

TOI



AGAIN MADE HISTORY



UTERINE PEDICAL
ACHIEVED IN
DONOR

AGAIN MADE HISTORY



Thank you....

Masters Course in Exposure, Retraction & Deep Dissection:

Challenging Robotic Surgeries

Kristin Patzkowsky, MD
Assistant Professor of Gynecology
Director, Fellowship Minimally Invasive Gynecologic Surgery
Johns Hopkins School of Medicine
Baltimore, MD

December 1, 2022




Disclosure

- I have no financial relationships to disclose.




What's Challenging?

- **Advanced Endometriosis**
- High order myomectomies
- Massive uteri hysterectomy
- C-section scar defect repair



What's Challenging?

- Advanced Endometriosis
- **High order myomectomies**
- Massive uteri hysterectomy
- C-section scar defect repair




What's Challenging?

- Advanced Endometriosis
- High order myomectomies
- **Massive uteri hysterectomy**
- C-section scar defect repair



What's Challenging?

- Advanced Endometriosis
- High order myomectomies
- Massive uteri hysterectomy
- **C-section scar defect repair**



What's Challenging?

- Combo Pathology
- Obliterated Pathology



Objectives

- Illustrate techniques for tackling complex MIS surgical scenarios
- Recommend strategies for approaching complex pathology
- Discuss ways the robotic platform can be utilized to simplify challenging pathology



COMBO PATHOLOGY

CASE #1

37yo G1P1 s/p abd myomectomy with recurrent fibroids & bulk symptoms.


• Exam: midline vertical incision, 2cm supraumbilical hernia, 22wk size fibroid uterus with a cervical fibroid filling posterior cul-de-sac and deviating cervix anteriorly

- Procedure: TRH, BS
- EBL: 500cc
- Specimen weight: 1153g



T2 Sagittal

CASE #1: 22wk Fibroid Uterus with 10cm Cervical Fibroid



CASE #1: Total robotic hysterectomy for 22wk size fibroid uterus with 10cm cervical fibroid



CASE #2


45yo G1P0 s/p robotic LSO for stg IV endometriosis with recurrent pain & bleeding.

- Exam: 18wk size uterus, restricted mobility, short torso, narrow pelvis
- MRI: right ovarian endometrioma, adenomyosis and fibroids


- Procedure: TRH, RSO
- EBL: 150cc
- Specimen weight: 610g




CASE #2: 18wk Uterus with Stg IV endometriosis




CASE #2: Total robotic hysterectomy, RSO for fibroids, adenomyosis and stg IV endometriosis



Set It & Forget It!



Wristed rigid instruments




OBLITERATED PATHOLOGY



CASE #3

33yo G0 with AUB, worsening dysmenorrhea.

- Exam: relatively mobile uterus, non-palpable adnexa
- MRI: left hematosalpinx and left ovarian endometrioma
- Procedure: Robotic LSO, myomectomy
- EBL: 200cc




CASE #3: Left Hematosalpinx & Endometrioma




CASE #4


- 48yo G3P0 s/p abdominal myomectomy x2, hsc myo x2, RFA with symptomatic fibroids.
- 2nd abd myo c/b severe adhesions with enterotomies requiring SB resection and reanastomosis.
 - Exam: short torso, 18wk size uterus, relatively mobile
 - Procedure: TRH, BS
 - EBL: 175cc
 - Specimen weight: 605g



CASE #4:




CASE #4




CASE #5

46yo G3P2 with worsening dysmenorrhea and 6cm right ovarian endometrioma.

- Exam: 8wk size retroverted uterus with restricted mobility, bilateral firm adnexal masses posterior to the uterus
- Procedure: TRH, BSO
- EBL: 100cc
- Specimen weight: 172g




CASE #5:



CASE #6:


35yo G3P2 with AUB, dysmenorrhea secondary to hematosalpinges, endometriomas and adenomyosis, s/p aborted laparoscopy, desires definitive treatment.

- Exam: 10wk size RV uterus, well suspended, minimally mobile
- Procedure: TRH, BSO
- EBL: 150cc
- Specimen weight: 184g



Coronal T2

CASE #6:



Global View of Pelvis

CASE 6

- VIDEO

What do these cases have to do with each other?

The Simple Secret.... Retract, Expose, Dissect

- Know anatomy
- Normalize Anatomy
 - Create normal
 - Go Retroperitoneal
 - Identify and dissect your deep pelvic spaces
- Circle the beast
- Don't be dogmatic
- "Let me see what I can do"
- Use the robot to your benefit!

Benefits of the Robot for Complex Pathology


Complex Dissections

- 3-D visualization
- Wristed instruments
- Not assistant dependent (4th arm)
- Can get into & hold deep space dissections without fatigue


Large Pathology

- RIGID instrument shaft
- Wristed instruments
- Xi- easy port hopping
- Can maintain hold of a large uterus without fatigue

Improved visualization



Laparoscopic View



Robotic View

Why the Robot?




Bend of Laparoscopic Instrument




Bend of Robotic Instrument

Rigid Instruments



Human Manipulation



Robotic Manipulation

After 3 hrs of adhesiolysis...



Laparoscopic fatigue




Robotic fatigue

References

1. Puntambekar S, Manchanda R. Surgical pelvic anatomy in gynecologic oncology. Inj J Gynecol Obstet. 2018; 143:86-92.

THANK YOU





Transvaginal Complex Gynecologic Surgery

John B. Gebhart, MD, MS
Professor of OBGYN, Urology and Surgery
Division Chair – Urogynecology
Mayo Clinic
Rochester, MN, USA

©2015 MFMER | slide 1

Disclosure

- Advisory Board - UroCure
- Royalty: Elsevier, UpToDate



©2015 MFMER | slide 2

Learning objectives

- Share keys to “seeing” during vaginal surgery
- Tips and techniques for difficult transvaginal surgical situations



©2015 MFMER | slide 3

Focus for Today

- Visualization
- Anterior Entry
- Morcellation
- Advanced POP and it's challenges



©2015 MFMER | slide 4

Set-up


- Exposure = visualization
 - Positioning
 - Adequate anesthesia
 - Lighting
 - Retraction
 - Surgeon



©2015 MFMER | slide 5



©2015 MFMER | slide 6




VH: Anterior Entry


- Bladder drainage
- Anterior or posterior entry first?
- Initial incision
- Stay in the midline
- Dissect along the uterus "hug the uterus"



©2015 MFMER | 4/26/15



©2015 MFMER | 4/26/15



©2015 MFMER | 4/26/15



©2015 MFMER | 4/26/15

Difficult anterior entry videos







©2015 MFMER | 4/26/15

VH: Special circumstances

- Cervical elongation
- Morcellation
- Procidentia



©2015 MFMER | 4/26/15






Morcellation video



©2015 MPMER | 4/26/25



Ureter Video



©2015 MPMER | 4/26/25

Take Home Points

- Start with easy ones....
- Utilize techniques to “see” things better
- Recognize more challenging situations and learn techniques to help you overcome them.
- The more you do.....the more you can do!



©2015 MPMER | 4/26/25



Thank you

©2015 MPMER | slide 31

Single-site and vNOTES routes for Challenging Surgeries

Xiaoming Guan, MD, PhD
Professor

Division Chief & Fellowship Director of Minimally Invasive Gynecologic Surgery
Baylor College of Medicine, Houston, Texas



Disclosure

- Speakers Bureau for Applied Medical



Objectives

- Articulating single-site and vNOTES surgery exposure techniques
- Elaborating the benefits and tips and tricks of single-site and vNOTES surgery
- Demonstrating the complex surgeries through single-site or vNOTES routes




Rationale for SILS

	LESS	R-LESS	Multiport
Cosmesis	+++	+++	+
Ease of tissue retrieval	+++++	+++	+
Patient satisfactory	+++++	+++++	+++
Quality of life analysis	++	++	++
Standard instrumentations	++	+++	++++
Not violate natural orifices	+++++	+++++	+

Robotic Single Site Instruments



Robotic Xi system docking




Video will be played during lecture

Setup: Port placement



Exposure techniques from open surgery



Surgical exposure is the foundation of all surgery

- Single-site surgery has exposure issues due to limited help from assistants
- Surgical exposure includes
 1. Clear and smoke-free total surgical field of view
 2. Exposure of Local Surgical site – uterine manipulator, Head Down
 3. Consider a single-site plus one
- The surgeon should decide the exposure of the operation according to the difficulty of the operation

Air seal

Small open with low suction flow

Suction irrigation

Single-site surgery gas control techniques

ALLY Uterine Positioning System*



Using needles and threads to remove the tissues that obstruct the field of vision, it can be fixed on the abdominal wall, which can make the operation more effective with less effort.

Video will be played during lecture

Video will be played during lecture

• Video will be played during lecture


Combined exposure

Single-site surgery exposure techniques

Zheng's 4C Suspension Method - Cross Suspension Method :

- When suspending the left uterine horn, select the needle insertion point about 10 cm above the right outer side of the umbilicus
- Then cross to the left uterine angle, suture the left adnexa and the left uterine corner, pay attention to suture the free left teres ligament broken end inside, in order to increase the traction tension of the parametrium
- Use curved forceps and small gauze to fix the suspension wire on the abdominal wall outside the body after the needle is drawn
- Suspend the right uterine horn on the left anterior abdominal wall in the same way

Inside & Outside Wisdom of the Suspension



王卡娜, 唐思敬, 郑亚. 郑氏4C悬吊法在经脐单孔腹腔镜妇科恶性肿瘤手术中的应用[J]. 中华腔镜外科杂志(电子版). 2022;14(10):5-8.
Chen S, et al. J Minim Invasive Gynecol. 2020 Nov-Dec;27(7):1473-1472.

Robotic-Assisted Laparoscopic Ureterolysis for Deep Infiltrating Endometriosis Using Indocyanine Green Under Near-Infrared Fluorescence

Authors: Taggart T, Tanaka Kyohiro T, Klemm Susan T
Affiliations: n hospital
PMID: 36101876 DOI: 10.1093/mjg/2022.01.018

Abstract
Objective: To demonstrate safe identification of ureters in patients with deep infiltrating endometriosis or severe adhesive disease using indocyanine green under near-infrared fluorescence on the robotic platform.
Design: Descriptive demonstration using narrated video footage.
Setting: An academic tertiary care hospital. A 43-year-old G2 with stage IV endometriosis presented with chronic pelvic pain. Her surgical history is notable for two abdominal hysterectomies due to severe adhesive disease, despite extensive lysis of adhesions. She desired surgical resection.
Interventions: In cases of stage IV endometriosis, localizing the ureters can be challenging due to severe adhesive disease, surrounding fibrotic tissue, and distorted anatomy. Intravenous indocyanine green has previously been described to assist with resection of endometriosis.¹⁻³ Alternatively, we describe a technique that allows for easier identification of ureters using indocyanine green (ICG) injection retrogradely in uterine stents while visualized under near-infrared fluorescence (NIRF).⁴⁻⁵
Conclusion: In cases of stage IV endometriosis, localizing the ureters can be challenging due to severe adhesive disease, surrounding fibrotic tissue, and distorted anatomy. Intravenous indocyanine green has previously been described to assist with resection of endometriosis.¹⁻³ Alternatively, we describe a technique that allows for easier identification of ureters using indocyanine green (ICG) injection retrogradely in uterine stents while visualized under near-infrared fluorescence (NIRF).⁴⁻⁵
Keywords: 1. Perform cystoscopy and place bilateral open-ended 5-French ureteral catheters. Inject indocyanine green retrogradely in each ureteral catheter, and place open to use the catheters to maximize ICG retention.² 2. Once robotic-assisted laparoscopic surgery is started, use NIRF to identify the ureters. The ureter will emit green fluorescence, whereas the surrounding tissue will not. 3. Once the ureter is identified, NIRF is intentionally used to safely follow the course of the ureter and perform ureterolysis, while avoiding endometriosis. The patient underwent robotic-assisted total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, bilateral omentectomy, low anterior bowel resection with primary anastomosis, and resection of endometriosis without intraoperative complications or ureteral injury. Her postoperative course was unremarkable. At her 3-week postoperative visit, pelvic pain had completely resolved.
Conclusions: This case demonstrates the use of intra-uterine ICG and NIRF to identify the ureters.

Video will be played during lecture

- 40 yo, Asian, G1P2, Chronic pelvic pain for 25 years, CS for twin
- Rectal exam left posterior 4-5 cm nodule
- MRI: Bowel endometriosis with left pelvic nodule about 5 cm

Video will be played during lecture

- 35 yo, G1P1, stage IV endo and ovarian remnant

Surgical history:

- 2004, NSVD, complication of placenta retain, exploratory laparotomy
- 2004, TVH due to bleeding
- 2004 Exploratory for bleeding,
- 2017 exploratory LSO
- 2018 RSO with appendix
- 2019, SILS resection of endo,

Pain 8/10, most in her left pelvic

MRI: There are proteinaceous/hemorrhagic masses in the pelvis. These are larger or new since the prior study. These may be related to endometriosis/endometriomas. fluid collection in the pelvis anterior to the rectum is smaller.

Video will be played during lecture

Video will be played during lecture

Video will be played during lecture

Author	Year	Country	No. of patients	Indication	Outcome
Li YC ^{1,2}	2016	Taiwan	33	33 patients had ovarian masses	robot-assisted NOTES hysterectomy
Xu BQ ³	2016	China	2016	18 patients had tubal ectopic pregnancy	robot-assisted NOTES hysterectomy
Boelelaert J ⁴	2016	Belgium	10	All patients had benign gynecological diseases	robot-assisted NOTES hysterectomy
Lee CL ⁵	2015	Taiwan	2015	All patients had benign gynecological diseases	robot-assisted NOTES hysterectomy
Sarah W ⁶	2015	Belgium	2015	All patients had ectopic pregnancy	robot-assisted NOTES hysterectomy
Wang CJ ⁷	2015	Taiwan	149	All patients had uterine myomas, adenomyosis, severe cervical dysplasia and endometriosis/hypertrophy	robot-assisted NOTES hysterectomy
Wang CJ ⁷	2015	Taiwan	2015	All patients had ovarian masses	robot-assisted NOTES hysterectomy
Reynders A ⁸	2015	Belgium	2015	All patients had benign gynecological diseases	robot-assisted NOTES hysterectomy
Loe CL ⁵	2014	Taiwan	137	All patients had benign gynecological diseases	robot-assisted NOTES hysterectomy
Loe CL ⁵	2014	Taiwan	2014	3 patient had early stage endometrial cancer	robot-assisted NOTES hysterectomy
Yang YS ⁹	2013	Korea	2013	7 patients had adnexal masses	robot-assisted NOTES hysterectomy
Li YC ^{1,2}	2012	Taiwan	2012	All patients had benign uterine diseases	robot-assisted NOTES hysterectomy
Alm KH ¹⁰	2012	Korea	2012	4 patients had benign uterine diseases	robot-assisted NOTES hysterectomy

Li CB, Hua KQ. Transvaginal natural orifice transluminal endoscopic surgery (vNOTES) in gynecologic surgeries: A systematic review. Asian J Surg. 2020 Jan;43(1):44-51. doi: 10.1016/j.asjsur.2019.07.014. Epub 2019 Aug 20. PMID: 31444108.

At this stage, robot-assisted NOTES is only useful for limited applications in highly selected patients

Early literature: Robotic NOTES gynecologic surgery

Tamisa Koythong, MD, Brooke Thigpen, MD, Sowmya Sunkara, MD, Hadi Erfani, MD, Stephanie Delgado, MD, and Xinming Guan, MD, PhD

From the Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas (all authors)


ABSTRACT Study Objective: To evaluate the safety and feasibility of robot-assisted transvaginal natural orifice transluminal endoscopic surgery (R-NOTES) hysterectomy when compared with traditional NOTES (T-NOTES) hysterectomy.

Table 3

Surgical outcomes between the 2 study groups (N = 114)

Surgical outcome	T-NOTES N = 79	R-NOTES N = 35	p-value	p-value (adjusted)
Estimated blood loss, mL	50 [25–150]	50 [30–100]	.70	.27
Length of surgery, min	143 [114–181]	157 [123–180]	.33	.37
Length of hospital stay, d	0 [0–1]	0 [0–1]	.07	.06
Weight of uterus, g	175 [92–393]	100 [79–229]	.06	.08
Pain score, wk 1	5 [2–8]	6 [4–8]	.62	.78
Pain score, wk 2	3 [0–6]	4 [2–6]	.38	.36
Pain score, wk 3	1 [0–4]	2 [0–4]	.50	.38
Conversion	6 (7.6)	0	.17	.13

R-NOTES = robot-assisted vaginal natural orifice transluminal endoscopic surgery; T-NOTES = traditional vaginal natural orifice transluminal endoscopic surgery. Variables are reported as median [interquartile range] (Mann-Whitney U test) and n (%). Fisher exact test. Adjustments were made for variables age and race/ethnicity using regression analysis.




Transvaginal NOTES Benefits



LMP 04/13/2018 (Exact Date) BMI 41.79 kg/m2

Wound infection

- Eliminating The risk.



- | | | |
|--------------------------|---------------------------|-----------------------------|
| "Self-evidence" benefits | No visible scars-cosmesis | No wound infection |
| No hernias | Less abdominal wall pain | Less adhesion |
| As a "rescue" | Non-descent uterus | Articulated instrumentation |




NOSCAR®

Natural Orifice Surgery Consortium for Assessment and Research (NOSCAR)®


Instruments for Robotic vNOTES

- 30-degree 8 mm R-scope
- TVH instrumentation
- Laparoscopic Grasper
- Bipolar, Monopolar scissor, vessel sealer
- Airseal
- Single site port (all types)

Da Vinci Vessel Sealer Extend



Robotic Xi system side docking



Packed around the specimen

Video will be played during lecture

Video will be played during lecture

WAVE sign for vNOTE anterior coloptomy-Thailand

Video will be played during lecture

Video will be played during lecture

What Have been done in Robotic VNOTES?

- Hysterectomy
- Adnexal surgeries
- Myomectomy
- High uterosacral ligament suspension
- Sacrocolpopexy
- Endometriosis resection
- Cancer surgery (not yet)

2.335 kg=5.15 lbs fibroid

Video will be played during lecture

Video will be played during lecture

Video will be played during lecture

Video will be played during lecture

References

1. Su H, Yen CF, Wu KY, Chen LH, Lee CL. Hysterotomy via transvaginal natural orifice transanal endoscopic surgery (NOTES): feasibility of an innovative approach. *Taiwan J Obstet Gynecol*. 2012;51(2):217-221. doi:10.1016/j.tjog.2012.02.009
2. 王淑娟, 葉文輝, 吳國宇, 陳麗華, 李麗玲. 經陰道自然腔道經肛門內視鏡手術之可行性研究. 中國醫藥雜誌 (電子版). 2012;14(1):15-9.
3. Zhenkun Chen, Samir D. Sork, Jean Sork, Soyoung Saitani, Xiaoming Guo. Cytoscopic-guided Robotic Resection of Bladder Triptone Endometriosis Nodules with Uteral Preservation. *J Minim Invasive Med*. 2015;25(1):1-6. doi:10.1016/j.jmim.2014.11.005
4. Brooke Thigpen, Temmie Kuyithong, Xiaoming Guo. Robotic-assisted Laparoscopic Uteroscopy for Deep Infiltrating Endometriosis Using Intrauterine Green Under Near-Infrared Fluorescence, Journal of Minimally Invasive Gynecology. 2015; 23(3):343-348. doi:10.1016/j.jmig.2014.12.012
5. Tamara Kuyithong, Brooke Thigpen, Soyoung Saitani, Hsien Tsai, Alexander Delgado, Xiaoming Guo. Robotic outcomes of hysterectomy via robotic-assisted transvaginal natural orifice transanal endoscopic surgery (NOTES) for benign gynecologic diseases. *Journal of Minimally Invasive Gynecology*. 2015; 23(3):349-354. doi:10.1016/j.jmig.2014.12.013
6. Xiaoming Guo, Brooke Thigpen, Tamara Kuyithong, Jian Liu. Robotic-assisted Transvaginal Single-site Laparoscopic Surgery for Pelvic Organ Prolapse. *J Minim Invasive Gynecol*. November 26, 2016. doi:10.1016/j.jmig.2016.11.013
7. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
8. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
9. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
10. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
11. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
12. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
13. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
14. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
15. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
16. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
17. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
18. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
19. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
20. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
21. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
22. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
23. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
24. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
25. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
26. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
27. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
28. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
29. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
30. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
31. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
32. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
33. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
34. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
35. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
36. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
37. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine Manipulation for FIGO B1 Cervical Cancer. *J Minim Invasive Med*. 2015;25(2):171-172. doi:10.1016/j.jmig.2015.02.003
38. Chen Y, Zheng Y, Tian H, Chen J, Chen J, Wang Y. Laparoscopic Single-site Radical Hysterectomy with Vaginal Closure and without Uterine

CULTURAL AND LINGUISTIC COMPETENCY & IMPLICIT BIAS

The California Medical Association (CMA) announced new standards for Cultural Linguistic Competency and Implicit Bias in CME. The goal of the standards is to support the role of accredited CME in advancing diversity, health equity, and inclusion in healthcare. These standards are relevant to ACCME-accredited, CMA-accredited, and jointly accredited providers located in California. AAGL is ACCME-accredited and headquartered in California.

CMA developed the standards in response to California legislation ([Business and Professions \(B&P\) Code Section 2190.1](#)), which directs CMA to draft a set of standards for the inclusion of cultural and linguistic competency (CLC) and implicit bias (IB) in accredited CME.

The standards are intended to support CME providers in meeting the expectations of the legislation. CME provider organizations physically located in California and accredited by CMA CME or ACCME, as well as jointly accredited providers whose target audience includes physicians, are expected to meet these expectations beginning January 1, 2022. AAGL has been proactively adopting processes that meet and often exceed the required expectations of the legislation.

CMA CME offers a variety of resources and tools to help providers meet the standards and successfully incorporate CLC & IB into their CME activities, including FAQ, definitions, a planning worksheet, and best practices. These resources are available on the [CLC and IB standards page](#) on the CMA website.

Important Definitions:

Cultural and Linguistic Competency (CLC) – The ability and readiness of health care providers and organizations to humbly and respectfully demonstrate, effectively communicate, and tailor delivery of care to patients with diverse values, beliefs, identities and behaviors, in order to meet social, cultural and linguistic needs as they relate to patient health.

Implicit Bias (IB) – The attitudes, stereotypes and feelings, either positive or negative, that affect our understanding, actions and decisions without conscious knowledge or control. Implicit bias is a universal phenomenon. When negative, implicit bias often contributes to unequal treatment and disparities in diagnosis, treatment decisions, levels of care and health care outcomes of people based on race, ethnicity, gender identity, sexual orientation, age, disability and other characteristics.

Diversity – Having many different forms, types or ideas; showing variety. Demographic diversity can mean a group composed of people of different genders, races/ethnicities, cultures, religions, physical abilities, sexual orientations or preferences, ages, etc.

Direct links to AB1195 (CLC), AB241 (IB), and the B&P Code 2190.1:

[Bill Text – AB-1195 Continuing education: cultural and linguistic competency.](#)

[Bill Text – AB-241 Implicit bias: continuing education: requirements.](#)

[Business and Professions \(B&P\) Code Section 2190.1](#)

CLC & IB Online Resources:

[Diversity-Wheel-as-used-at-Johns-Hopkins-University-12.png \(850×839\) \(researchgate.net\)](#)

[Cultural Competence In Health and Human Services | NPIN \(cdc.gov\)](#)

[Cultural Competency – The Office of Minority Health \(hhs.gov\)](#)

[Implicit Bias, Microaggressions, and Stereotypes Resources | NEA](#)

[Unconscious Bias Resources | diversity.ucsf.edu](#)

[Act, Communicating, Implicit Bias \(racialequitytools.org\)](#)

<https://kirwaninstitute.osu.edu/implicit-bias-training>

<https://www.uptodate.com/contents/racial-and-ethnic-disparities-in-obstetric-and-gynecologic-care-and-role-of-implicitbiases>

<https://www.contemporaryobgyn.net/view/overcoming-racism-and-unconscious-bias-in-ob-gyn>

<https://pubmed.ncbi.nlm.nih.gov/34016820/>